Please select the option that best describes you:
In what situations, if any, would you recommend NALIRIFOX over FOLFIRINOX for first-line treatment of patients with unresectable pancreatic cancer?
Given the recent update from the NAPOLI-3 trial presented at GI ASCO 2023, the two regimens appear to have similar OS.
Answer from: Medical Oncologist at Academic Institution
Fully agree with answers/comments above that with current evidence I cant see any scenario where I would use NALIRIFOX instead of FOLFIRINOX.There is no difference in neurotoxicity or response rate. Neurotoxicity was underreported in final publication and response rate overestimated due to lack of B...
Medical Oncologist
This question relates to "unresectable" pancreas cancer. The NAPOLI-3 trial included previously untreated patients with metastatic cancer. At a median follow-up of 16.1 months, median overall survival was 11.1 months with Nalirifox compared to 9.2 months with nab-paclitaxel and gemcitabine. However,...
Do you feel there is a difference in the toxicity ...
The only difference is the reduced neurotoxicity a...